Genomic imprinting plays an important role in mammalian development. Loss of imprinting (LOI) through loss (LOM) or gain (GOM) of methylation is involved in many human disorders and cancers. The imprinted 11p15 region is crucial for the control of foetal growth and LOI at this locus is implicated in two clinically opposite disorders: Beckwith Wiedemann syndrome (BWS) with foetal overgrowth associated with an enhanced tumour risk and Russell-Silver syndrome (RSS) with intrauterine and postnatal growth restriction. So far, only a few studies have assessed multilocus LOM in human imprinting diseases. To investigate multilocus LOI syndrome, we studied the methylation status of five maternally and two paternally methylated loci in a large series (n 5 167) of patients with 11p15-related foetal growth disorders. We found that 9.5% of RSS and 24% of BWS patients showed multilocus LOM at regions other than ICR1 and ICR2 11p15, respectively. Moreover, over two third of multilocus LOM RSS patients also had LOM at a second paternally methylated locus, DLK1/GTL2 IG-DMR. No additional clinical features due to LOM of other loci were found suggesting an (epi)dominant effect of the 11p15 LOM on the clinical phenotype for this series of patients. Surprisingly, four patients displayed LOM at both ICR1 and ICR2 11p15. Three of them had a RSS and one a BWS phenotype. Our results show for the first time that multilocus LOM can also concern RSS patients. Moreover, LOM can involve both paternally and maternally methylated loci in the same patient.
INTRODUCTION
Genomic imprinting is an epigenetic mechanism whereby expression of a subset of genes is restricted to a single parental allele. In humans, at least 80 genes are imprinted. The majority of these genes are organized in clusters throughout the genome and are regulated by an imprinting control region (ICR) (1, 2) . ICRs are methylated during gametogenesis in a parent-specific manner on cytosine residues of the CpG dinucleotides. This differential methylation regulates the allele-specific expression of several genes in a cluster. All of the ICRs except three are maternally methylated. In mammals, imprinted genes play important roles in pre-and postnatal growth and behaviour (3, 4) . Loss of imprinting (LOI) through gain or loss of DNA methylation is implicated in several human diseases and cancer (5) .
The human chromosome 11p15 encompasses two imprinted domains important in the control of foetal and postnatal growth. Each domain is differentially methylated and regulated by its own ICR (ICR1, which is paternally methylated, within the telomeric region, regulating the H19/IGF2 domain; and ICR2, which is maternally methylated, within the centromeric region regulating the KCNQ1/CDKN1C domain). LOI of these two domains is implicated in two clinically opposite growth disorders. A loss of DNA methylation (LOM) at ICR1 is found in over 50% of patients with Russell -Silver syndrome (RSS) (6, 7) , whereas a gain of DNA methylation (GOM) at ICR1 results in 10% of patients with Beckwith Wiedemann syndrome (BWS) (8) . Abnormal DNA methylation (LOM) at ICR2 only results in BWS (60% of BWS cases) (8) (Fig. 1) .
The mechanisms leading to establishment and maintenance of allele-specific DNA methylation at ICRs, throughout development, are very complex and not fully understood. They involve not only cis-and transacting regulatory factors (9, 10) but also environmental factors such as diet (11, 12) . Assisted reproductive technology (ART) procedures provide the possibility of assessing the effect of the pre-and early postfertilization environment on epigenetic regulation. Clinical studies have indeed shown a significant increase in the risk of human imprinting diseases such as BWS and Angelman syndrome (AS) associated with ART (13 -16) .
Several groups, including ours, have demonstrated that DNA methylation defect is not always restricted to one locus in LOI patients, but may involves other imprinted loci as well. Our group has reported a subset of BWS patients (25%) with LOM at ICR2 11p15, conceived spontaneously or after ART, who also had LOM at other maternally methylated loci (17) . Bliek et al. (18) also reported a subset (21%) of BWS patients with LOM at maternally methylated loci other than ICR2 11p15. Lim et al. (19) found a significant difference in the number of BWS cases due to ICR2 11p15 LOM with additional LOM at 6q24, 7q32 and 15q13 between patients conceived by ART (37.5%) and patients conceived spontaneously (6.4%), but found no LOM at DLK1/GTL2 IG-DMR in these populations. Mackay et al. (20) reported a subset of patients (50%) with transient neonatal diabetes mellitus (TNDM) with LOM at 6q24 and other maternally methylated loci. These authors proposed the existence of a maternal hypomethylation syndrome (20, 21) . Currently, no Figure 1 . Representation of the 11p15 region and its imprinting related disorders. The middle panel represents the normal situation. The 11p15 region encompasses two imprinted centres, ICR1 at the telomeric part and ICR2 at the centromeric one. ICR1 is methylated on the paternal allele to which CTCF does not bind thereby allowing the shared enhancers (E) to access IGF2 promoters and stimulate their activation. On the maternal allele, however, ICR1 is not methylated and CTCF can bind and plays an insulator role preventing the shared enhancers to activate IGF2 promoters but permitting the activation of the H19 promoter. ICR2 is methylated on the maternal allele where CDKN1C and KCNQ1 are expressed. On the paternal unmethylated allele, KCNQ1OT1 (non-coding RNA) is expressed and regulates the imprinting in cis. Two imprinting defects can lead to BWS: the first is LOM at ICR2 (upper left panel) leading to biallelic expression of KCNQ1OT1 and loss of expression of CDKN1C and KCNQ1. This abnormality accounts for 60% of BWS. The second is the GOM at ICR1 (upper right panel) leading to biallelic expression of IGF2 (main foetal growth factor) and down regulation of H19. This abnormality accounts for 10% of BWS. In over 50% of RSS patients, LOM at ICR1 is involved (lower middle panel). This anomaly leads to down regulation of IGF2 and biallelic expression of H19. study of multilocus defect on a large cohort of RSS with 11p15 LOM has been monitored. Schonherr et al. (22) did not identify any methylation abnormalities at 14q32, 6q24 and ICR2 at 11p15 regions in a population of RSS patients with maternal uniparental disomy of chromosome 7 (mUPD7, n ¼ 10) or LOM at ICR1 at 11p15 (n ¼ 22).
To investigate multilocus defects in human imprinting disorders, we analysed a large series (n ¼ 192) of RSS and BWS patients comprising a well-characterized cohort of 11p15 related foetal growth disorders (n ¼ 167) and a group of RSS patients without yet identified molecular cause (n ¼ 25). We studied the methylation status of seven imprinted loci, most of them implicated in human imprinting disorders. We investigated five maternally methylated loci [ZAC1 at 6q24 implicated in TNDM, IGF2R at 6q26 involved in Large Offspring Syndrome (LOS) in cattle and sheep (23, 24) , PEG1/MEST at 7q32 which paternal knockout allele causes IUGR and behaviour defect in mice (4), ICR2 at 11p15 implicated in BWS and SNRPN at 15q11 -13 the locus involved in Angelman and Prader Willi syndromes] and two paternally methylated loci ICR1 at 11p15 involved in BWS and RSS, and DLK1/GTL2 at 14q32 where an anomaly causes distinct clinical features, depending on parent origin transmission (25, 26) . We used Southern blotting as well as allele-specific methylated multiplex real time quantitative PCR (ASMM RTQ-PCR) following bisulphite treatment to analyse the methylation status of these loci. We demonstrate here for the first time that multilocus LOM also occurs in RSS patients with ICR1 11p15 LOM. Importantly, we found that LOM at DLK1/GTL2 IG-DMR, one of the three known paternally methylated ICR, is restricted to a subset of RSS patients with ICR1 LOM. Furthermore, we showed that LOM can involve both paternally and maternally methylated loci in the same patient.
RESULTS
We studied the methylation status of seven imprinted loci [five maternally methylated loci (ZAC1 at 6q24, IGF2R gene at 6q26, PEG1/MEST at 7q32, ICR2 at 11p15 and SNRPN at 15q11 -13) and two paternally methylated loci (ICR1 at 11p15 and DLK1/GTL2 at 14q32)] in leukocytes DNA extracted from a population of patients presenting BWS or RSS (74 RSS with LOM at ICR1 11p15; 68 BWS patients with LOM at ICR2 11p15; 25 BWS with GOM at ICR1 11p15 and 25 RSS with no identified molecular defect) and 75 control subjects. We used semi-quantitative and quantitative methods; Southern blotting and ASMM RTQ-PCR, respectively.
11p15 analysis
We had previously molecularly characterized the studied population by Southern blotting to assess the ICR1 and ICR2 11p15 methylation status. Moreover, the entire population was also studied by ASMM RTQ-PCR. The results for these two methods were concordant for both ICR1 and ICR2 11p15 methylation status (data not shown).
Multilocus methylation analysis
The methylation indexes (MI), mean and range, calculated from Southern blotting results for a control population, for IGF2R DMR2, PEG1/MEST, ICR2 11p15 and SNRPN were identical to those we previously reported (17) . The methylation status at ZAC1 DMR of 75 control subjects was analysed by Southern blot and the mean MI is shown in Table 1 .
Thereafter, 101 of the patient's cohort were analysed with Southern blotting at ZAC1 DMR, PEG1/MEST, SNRPN and IGF2R DMR2. ASMM RTQ-PCR was used to analyse 192 patients at all loci except IGF2R DMR2. The two methods gave similar MIs in all studied loci (data not shown).
No methylation defects were found in the loci studied in the RSS population without ICR1 11p15 LOM or BWS patients with ICR1 11p15 GOM (Table 1) . Hence, the results of multilocus LOM described below concern only the RSS and BWS with LOM at ICR1 (n ¼ 74) and ICR2 11p15 (n ¼ 68), respectively.
Multilocus methylation defect in RSS patients
Of the 74 RSS patients with ICR1 11p15 LOM, seven (9.5%) displayed multilocus methylation defects (Table 1 and 2; Figs 2 and 3A). Two patients (3%) showed LOM at ZAC1 DMR, three (4%) at the PEG/MEST locus, one (1.4%) at the SNRPN locus and two (3%) at IGF2R DMR2. It should be noted that three RSS patients (RSS3, RSS11 and RSS26) out of 74 (4%) with LOM at ICR1 11p15 also showed LOM at ICR2 11p15 (Tables 1 and 2 ). Moreover, five RSS patients (7%) also displayed LOM at DLK1/GTL2 IG-DMR.
Multilocus methylation defects in BWS patients
Sixteen BWS patients with ICR2 11p15 LOM out of 68 (24%) displayed LOM at least another imprinted region (Tables 1 and  2 ; Figs 2 and 3B). Six patients out of 68 (9%) had LOM at ZAC1 DMR, 6 (9%) had LOM at the PEG/MEST locus, 1 (1.5%) at the SNRPN locus and 10 (15%) patients displayed LOM at IGF2R DMR2. Interestingly, 1 BWS patient (BWS68) out of 68 (1.5%) with ICR2 11p15 LOM also displayed LOM at ICR1 11p15 (Tables 1 and 2 ). No methylation defect was found in DLK1/GTL2 IG-DMR.
Our results showed that a subset of RSS and BWS patients with ICR1 and ICR2 11p15 LOM, respectively, displayed LOM at other imprinted regions. Most patients had variable LOM indexes with some loci being more affected than others (Table 1) . BWS patients with ICR2 11p15 LOM had more frequent LOM at other maternally methylated regions than RSS patients with ICR1 11p15 LOM. Moreover, we showed that LOM could involve both paternally (ICR1 11p15 and DLK1/GTL2 IG-DMR) and maternally methylated loci (ZAC1DMR, IGF2R DMR2, PEG1/MEST locus, ICR2 11p15 and SNRPN locus) for the same patient. LOM of the paternally methylated locus DLK1/GTL2 IG-DMR was only identified in RSS patients with ICR1 11p15 LOM (Tables 1  and 2 ).
Multilocus methylation defect and clinical characteristics
RSS patients. There was no statistical difference between the RSS group of patients with ICR1 11p15 LOM only and the RSS group with multilocus LOM, regarding birth and growth parameters [assessed on Usher and McLean chart (27) ], cognitive development, glucose homeostasis and the number of patients in each group born after ART. Patient RSS11 displayed multiple LOM (six of seven loci studied) and presented a severe clinical spectrum, atypical for RSS. This patient was the child from a consanguineous union and presented severe IUGR and a major sexual ambiguity. He was raised as a female despite an XY karoytype and had surgery for gonad ablation. He also showed severe developmental delay and 'happy behaviour'. DNA methylation analysis of parental DNA was normal at the 11p15 region (data not shown). Three patients RSS3, RSS11 and RSS26 also had LOM at ICR2 11p15, but presented RSS and no sign of BWS. The two RSS patients (RSS26 and RSS44) with LOM at ZAC1 DMR did not have TNDM syndrome. Patient RSS26 also had LOM at five out of six loci studied (ICR1 and ICR2 11p15, ZAC1 DMR, PEG/MEST and DLK1/GTL2 IG-DMR), but had a mild RSS phenotype with no unusual symptoms. Overall, all RSS patients with multilocus LOM, except one (RSS11), had a typical RSS phenotype (Table 3) . BWS patients. Although some patients had LOM at various imprinted loci, the clinical presentation was of BWS. There were no significant clinical differences between BWS patients with LOM at ICR2 only and BWS patients with multilocus LOM, in terms of birth and growth parameters [assessed on Usher and McLean chart (27) ], tumour occurrence, cognitive development, glucose homeostasis and the number of patients in each group born after ART (Table 4) . Patient BWS68 had LOM at five out of seven affected loci and these anomalies concerned both maternal (ICR2 11p15, ZAC1 DMR, PEG/ No methylation abnormalities were found in BWS patients with GOM at ICR1 11p15 or in RSS patients without ICR1 11p15 defects.
MEST locus and IGF2R DMR2) and paternal (ICR1 11p15) loci. Patient BWS68 showed complete LOM at ICR2 in leukocyte DNA, whereas at other loci LOM including ICR1 was only partial (around 30%). This patient had both an ICR2 11p15 LOM and an ICR1 11p15 LOM and presented a BWS phenotype with macroglossia, umbilical hernia and no RSS clinical features. Other patients also displayed variations in the LOM indexes with some loci being more affected than others (Table 1 ; BWS1, BWS23, BWS48, BWS52 and BWS67). BWS patients with LOM at ZAC1 DMR did not exhibit a TNDM syndrome.
DISCUSSION
We studied the methylation status of seven imprinted loci (five maternal and two paternal) in a large cohort of RSS and BWS patients with 11p15-related foetal growth disorders. We used Southern blotting, and a newly developed quantitative technique, ASMM RTQ-PCR. We found that 9.5% of RSS patients had LOM at ICR1 11p15 and other imprinted loci. This is the first demonstration that multilocus defects also occur in RSS patients. Indeed, a previous study failed to identify LOM in RSS patients with mUPD7 or ICR1 11p15 LOM (22) . However, the small size of the RSS cohort (10 patients with mUPD7 and 22 patients with ICR1 11p15 LOM) previously studied could explain this discrepancy. Of the RSS patients with multilocus defects, 71% have LOM at DLK1/GTL2 IG-DMR, whereas no LOM at this locus was identified in BWS patients. RSS patients, therefore, had LOM of DLK1/ GTL2 IG-DMR and ICR1 11p15, both of which are paternally methylated. Bartholdi et al. (28) did not find LOM at this locus in three familial cases of RSS with LOM at ICR1 11p15. We also found that 24% of BWS patients with ICR2 11p15 LOM also had LOM at least at one other locus. Although, we have increased the number of patients and loci studied here, this percentage was consistent with our previous reports (17 Mackay et al. (21) reported that 50% of TNDM patients with LOM at the 6q24 locus also showed LOM at other maternally methylated loci. Hence, these authors suggested the existence of a maternal hypomethylation syndrome. Here, we showed that a subset of RSS patients with LOM at the paternally methylated ICR1 11p15 also had LOM at maternally methylated genes. Moreover, one BWS patient had a large spectrum of LOM at maternally methylated loci and also had LOM at the paternally methylated ICR1 11p15 locus. LOM can therefore involve both paternally and maternally methylated regions.
No significant differences in clinical features were observed between RSS and BWS with multilocus and monolocus LOM patients. These results agree with those reported for BWS cohorts with multilocus defects (17 -19). Although our study described a large cohort of patients, the number of patients with multilocus LOM, however, was still relatively small to enable definitive conclusions to be drawn regarding significant differences in clinical features. However, patient RSS11 with multilocus LOM had a more severe phenotype than that usually observed in RSS patients. The second locus most affected in the RSS population with multilocus defect is DLK1/GTL2 IG-DMR present in over two-thirds of this population. Patients with maternal UPD14 (matUPD14) are characterized by pre-and postnatal growth retardation, early onset puberty and variable intellectual outcome (29) . Only two patients with LOM at DLK1/GTL2 IG-DMR have been reported with a matUPD14-like phenotype (30, 31) . Though, the five RSS patients with LOM at this locus, except RSS11, did not show intellectual retardation or precocious puberty, while pre-and postnatal growth retardation are difficult to analyse, as they are already part of the RSS phenotype.
We found that 29% RSS and 38% BWS patients with multilocus LOM had LOM at ZAC1 DMR. TNDM patients are born with intrauterine growth retardation, present with severe failure to thrive in the first 6 weeks of life and suffer from diabetes resulting from insulin production failure (32) . As previously reported in BWS patients (18, 19) , despite LOM at ZAC1 DMR, neither the RSS nor the BWS patients in our study displayed TNDM. Although these studies showed LOM at the same imprinted loci, the patients studied by Mackay et al. (20) presented with TNDM and our patients presented with RSS or BWS. Methylation at the SNRPN locus was almost unaffected. Only two patients showed LOM at this locus; RSS11 had complete LOM and BWS52 had partial LOM (39%). Only 3% of patients with AS have an imprinting defect at SNRPN locus (33) . Moreover, the SNRPN imprint was shown to be resistant to changes in culture conditions of human embryonic stem cells (34, 35) . These last results suggest that the mechanisms regulating SNRPN imprint are well established at an early stage and probably make it less sensitive to mechanisms involved in the LOM.
It is striking that four patients had LOM at both ICR1 and ICR2. One of these patients had a BWS phenotype, while the three others had a RSS phenotype. It is still unclear why one syndrome is presented rather than another, although all these patients had LOM at multiple imprinted loci involved in different human syndromes. We suggest that greater demethylation gives the dominant phenotype. This hypothesis is supported by the observation that in TNDM patients the LOM at ZAC1 DMR is total, whereas the LOM at ICR2 11p15 locus is only partial (21) . This high level of LOM may, therefore, favour a TNDM and partially mask the expression of other phenotypes. In BWS or RSS patients, even when 11p15 LOM is similar to other affected loci, it leads to a RSS or a BWS phenotype rather than a TNDM when ZAC1 is also involved. An RSS and not a BWS phenotype is presented when LOM is involved at both ICR1 and ICR2 11p15 with comparable MIs, as in RSS3, RSS11 and RSS26 patients. Thus, the degree of demethylation of the different affected loci cannot always explain the dominant clinical phenotype of patients with multilocus LOM. One locus might have an (epi)dominant effect in some cases with comparable multilocus LOM. This seems to be the case in our cohort for the patients with ICR1 11p15 LOM and other affected loci. However, patient BWS68 had complete LOM at ICR2 but only partial LOM at ICR1 and had a BWS phenotype.
As previously reported (17, 18, 21) , the loss of methylation is most of the time partial and variable at the loci studied. This suggests an epigenetic mosaicism that may vary between tissues. In this study, only leukocytes DNA was analysed. This mosaicism could also explain the predominant clinical expression of a syndrome of LOM at one locus rather than another depending on the pattern of LOM at the loci concerned.
Given the co-existence of paternal and maternal LOM and the mosaic aspect of these anomalies, our findings reinforce the hypothesis that these epigenetic defects probably occurred postzygotically, rather than in germ line cells. This does not rule out, however, the involvement of a gametic transacting factor implicated in the maintenance of imprints after fertilization.
Because LOM at DLK1/GTL2 IG-DMR was only identified in RSS patients with multilocus methylation defects and not in BWS patients, the factors leading to the establishment and/or the maintenance of the paternal and maternal imprint are probably different, although some may regulate both imprints. Some factors involved in the apposition of specific parental methylation at ICR have been identified. CTCFL/BORIS, a testis-specific factor, may specifically re-establish methylation at paternally methylated loci, ICR1 11p15 and DLK1/GTL2 IG-DMR (36) . The crucial roles of the DNMTs in the establishment (Dnmt3a and Dnmt3l in the female germline) and maintenance (DNMT1 and its specific ovarian isoform, DNMT1o) of the imprints are largely documented in murin models (37 -40) . However, no mutations of DNMT3L were found in mothers of two BWS patients with severe hypomethylation at various maternally methylated loci (18) . Moreover, methylation analysis of classical and a-satellites in BWS patients with multilocus LOM showed normal methylation, ruling out a genomewide demethylation and DNMT1 defect (17) . This suggests that other key regulators are involved in the establishment and maintenance of the parental imprints. ZFP57 (a zinc-finger transcription factor) mutations have been reported to be associated with multilocus defects in TNDM patients (41) . Moreover, NLRP2 mutation has been identified in two children from a BWS consanguineous family with LOM at ICR2 11p15. One of them also showed LOM at the PEG1 locus (42) . Imprinting may be maintained by PGC7/Stella during the preimplantation period. PGC7/ Stella-null mice fail to maintain imprinting at some maternally methylated loci and two paternally loci, H19 ICR and Rasgrf1, but the Dlk1/Gtl2 locus is unaffected. Remarkably, LOM at these loci is partial (43) .
It appears that the environment acts through epigenetic mechanisms to modulate development (11) . Animal model studies showed the effect of embryonic culture on the stability of genomic imprinting (44, 45) . Several clinical studies demonstrated that ART significantly increased the risk of human imprinting diseases such as BWS and AS (13 -16) . We also observed an increased risk of RSS associated with ART in our cohort of RSS patients with ICR1 11p15 LOM (manuscript in preparation). However, no RSS patient born after ART procedures had multilocus defects in our cohort. Moreover, in our cohort of BWS, there was no significant difference between the incidence of monolocus and multilocus LOM in patients conceived after ART. This agrees with our earlier findings (17) and suggests that ART procedures increase the risk of imprinting defects but are not the only cause of multilocus LOM. However, Lim et al. (19) found a significant difference between the incidence of multilocus defects in their ART versus non-ART BWS patients with LOM at ICR2 11p15, but only a few patients of their ART group (n ¼ 8/24) were analysed.
We found no multilocus methylation anomalies in the population of BWS patients with GOM at ICR1 11p15 region and, in particular, no GOM in the DLK1/GTL2 IG-DMR locus. This agrees with the results of others (18, 46) and suggests that the molecular mechanism involved in GOM is different from that implicated in LOM.
In conclusion, in a large cohort of 11p15-related foetal growth disorders, we confirmed that 24% of BWS show multiple LOM. For the first time, we showed that multilocus LOM also concern 10% of RSS patients and that DLK1/ GTL2 IG-DMR, one of the rare paternally methylated ICR, is hypomethylated in over two-thirds of the RSS patients with multilocus defects. Importantly, we demonstrated that LOM can occur at both paternally and maternally methylated regions in the same patient. This suggests that the expression of this LOI occurs in the postzygotic period and probably involves abnormalities in the maintenance of parental imprinting. Finally, although this series of RSS and BWS patients had LOM at loci involved in other human diseases, they did not generally show evidence of other clinical disorders. This is consistent with a phenotypic (epi)dominance of the 11p15 region LOI in our series of patients.
MATERIALS AND METHODS

Patients
The study was conducted in accordance with national ethics regulations (agreement numbers 681 and 682, Assistance Publique-Hôpitaux de Paris). Informed consent for genetic analysis was obtained from patients or their parents. Genomic DNA was extracted from leukocytes of each patient using standard techniques. One hundred and ninety-two patients with BWS or RSS were analysed. Of these, 167 had 11p15 related foetal growth disorders (74 RSS patients with paternal ICR1 11p15 LOM, 68 BWS patients with maternal ICR2 11p15 LOM and 25 BWS patients with maternal ICR1 11p15 GOM). Twenty-five RSS patients with no identified molecular anomaly (neither ICR1 11p15 LOM nor mUPD7) were also analysed. Patients were clinically diagnosed with RSS if they showed at least three out of five of the criteria on the scoring system we previously published (7). All BWS patients had molecular abnormalities. A subset of the BWS population with ICR2 11p15 LOM (n ¼ 31) was previously reported by our group (17) and was further analysed at ZAC1 DMR and DLK1/GTL2 IG-DMR in this study.
DNA methylation analysis
All the loci were analysed by ASMM RTQ-PCR and Southern blotting except IGF2R DMR2 and DLK1/GTL2 IG-DMR which were only analysed by Southern blotting and ASMM RTQ-PCR, respectively.
Southern-blot analysis
We used methyl-sensitive Southern blotting to analyse the methylation status of six genes mapping to five imprinted loci (6q24, 6q26, 7q32, 11p15.5 and 15q11 -13). The methylation status of ICR1 and ICR2 at 11p15.5, IGF2R DMR2 at 6q26, PEG/MEST at 7q32 and the SNRPN CpG island at 15q11 -13 was analysed as described previously (8, 17, 47, 48) . For the methylation status of ZAC1 DMR (6q24), 5 mg of genomic DNA were digested with PstI and then with the methylation-sensitive enzyme, SmaI and then subjected to electrophoresis in 1.3% agarose gel and blotted onto a Hybond-XL membrane (GE Healthcare, Orsay, France). PCR was used to synthesize the probe used for hybridization, which was a 717 bp fragment in the CpG island (GeneBank accession number AL109755, nucleotides 51539-52255) for ZAC1 DMR. Methylation indexes were determined by densitometry of autoradiographs using a Storm PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA). NT_026437) . This quantitative method, using TaqMan probes, couples allelic discrimination and quantification using standard curves for each probe. Briefly, the multiplex amplification was performed on a 96 well plate in 20 ml reaction volume, containing 10 ng of sodium bisulfite treated genomic DNA (3 ml per well), 9 ml TaqMan Universal Master Mix (Applied Biosystems, France), 900 nM of each primer and 200 nM of each TaqMan-MGB probe.
Bisulfite treatment
The run was performed using SDS 3.2 software (ABI Prism 7900HT sequence detector; Applied Biosystems, France). All primers and probes were designed using Primer Express 3.0 software (Applied Biosystems, France). The amplification conditions, primers and probes are available upon request. The standard curve method was used to quantify each allele. A control DNA was used to monitor the standard curve using the following dilutions: 32, 10.67, 3.55, 1.19 and 0.4 ng. The results were analysed with SDS 2.3 software (Applied biosystems, France) and the MI [MI¼ quantity of the methylated allele Â 100/ (quantity of methylatedþ unmethylated allele)] calculated on Excel software.
We used EpiTect Control DNAs (QIAgen, France) to test the specificity of our probes. These DNAs are totally unmethylated or methylated, are pre-treated with sodium bisulfite and are ready to use.
DNA sequencing
To check primer specificity, the amplification products of each region were sequenced, with the same primers used in ASMM RTQ-PCR, the ABI PRISM BigDye Terminator v1.1 cycle sequencing kit and the ABI 3100 Genetic Analyser (Applied Biosystems). Sequences were analysed with Sequence Navigator and Edit View software (ABI Prism).
ASMM RTQ-PCR development
To check primer specificity, we firstly direct sequenced each locus to be studied using the same primers used in the ASMM RTQ-PCR. All the sequences had the expected C/T dinucleotide polymorphisms that we obtain after sodium bisulfite treatment. These results demonstrated the specificity of the primers used to amplify each region and the differential methylation state of the regions analysed. Secondly, we designed two TaqMan-MGB probes for each DMR hybridizing either the methylated or the unmethylated allele, encompassing at least two C/T polymorphisms to optimize stringency. The result obtained with EpiTect control DNAs is shown in Supplementary Material, Figure S1A . The probes designed to quantify each region were highly specific and did not show cross hybridization for the two alleles. Seventy-five control subjects were tested for each locus analysed; the mean and standard deviation (SD) of the methylation indexes (MI) were then calculated. The MIs calculated for Southern blotting and ASMM RTQ-PCR show concordant MI of each DMR (Supplementary Material, Fig. S1B and Table 1 ). An example of the amplification curves of a control subject and a patient with LOM at ZAC1 DMR is shown in Supplementary Material, Figure S1C and D. For each locus, we have considered an MI as normal if it was within the range expressed with mean MI value of the control population+2 SD and abnormal when outside of this range. ASMM RTQ-PCR was as effective as Southern blotting for studying imprinted regions.
Statistical analysis
The Student's t-test was used to analyse differences between the monolocus group and the multilocus group for continuous variables. The Mann -Whitney U test was used in the absence of a normal distribution. The Pearson chi-square test was used to analyse the difference in proportion of patients with certain clinical features between the group with multilocus abnormalities and the group with monolocus abnormalities; for small numbers, the Fisher's exact test was used. A P , 0.05 was considered significant. SPSS version 16.0 (SPSS, Inc., Chicago, IL, USA) was used for the calculations.
